The FDA has approved Janssen’s antidepressant nasal spray Spravato, making it the first new type of depression treatment to hit the market in 30 years – although its use will be restricted to ...

J&J's Spravato was FDA-approved in January as the only monotherapy for adults with treatment-resistant major depressive disorder. Feel unsure about the market’s next move? Copy trade alerts from ...

In January, 2025, J&J’s nasal spray Spravato secured a label expansion from the FDA for use as a single agent in adults with major depressive disorder (who were not responsive to two oral ...

Spravato has a boxed warning about this risk. A boxed warning is the most serious warning from the Food and Drug Administration (FDA). For details, see “Boxed warnings” in the introduction of ...

This is because the Food and Drug Administration (FDA) only approves the drug ketamine for use in general anesthetics. However, Medicare may cover the drug Spravato, which contains esketamine.

New Directions Mental Health's Greensburg clinic now offers SPRAVATO®, an FDA-approved nasal spray for fast relief from treatment-resistant depression. GREENSBURG, PA, UNITED STATES, March 26 ...